Camille Vaganay

Camille Vaganay

Auto-generated profile, based on publicly available information

Camille Vaganay

INSERM UMR 944, IRSL, St Louis Hospital, University of Paris-Cité, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Science Advances
Verified
Journal Article
Open access
RARuby Alonso
Ruby Alonso
ZGZacarias Garcia
Zacarias Garcia
BCBéatrice Corre
Béatrice Corre
FLFabrice Lemaître
Fabrice Lemaître
CVCamille Vaganay
Camille Vaganay
PBPhilippe Bousso
Philippe Bousso
Cancer therapies that induce immunogenic cell death such as necroptosis can arm the immune system to clear residual tumor cells. Receptor-interacting serine/threonine protein kinase 3 (RIPK3) signaling can trigger necroptosis, orchestrating immune responses to solid tumors. Whether RIPK3 activity can be exploited for controlling B cell malignancies remains unclear. Here, we establish a strategy to manipulate RIPK3 activity in malignant B cells and promote immune-mediated tumor control. By controlling and visualizing RIPK3 signaling using intravital imaging, we established that RIPK3 activation promoted apoptosis and rapid macrophage engulfment but failed to induce necroptosis due to limited MLKL expression in B-lineage cells. RIPK3-induced cell death could be diverted toward necroptosis with type I IFN and caspase inhibition. Exploiting these findings, we showed that a combination therapy activating RIPK3 with SMAC mimetics while suppressing caspase activity and providing type I IFN resulted in immune-mediated control of B cell tumors. Hence, reprogramming RIPK3 activity represents an attractive therapeutic opportunity to target B cell malignancies.

13 November 2019 in Blood
Verified
Journal Article
Open access
ASAngela Su
Angela Su
FLFrank Ling
Frank Ling
CVCamille Vaganay
Camille Vaganay
BPBryann Pardieu
Bryann Pardieu
LBLina Benajiba
Lina Benajiba
APAlexandre Puissant
Alexandre Puissant
Metabolic rewiring of neoplastic cells engenders metabolic liabilities that can be exploited to design innovative therapeutic strategies, including those to increase the therapeutic index of existing anticancer therapies. We hypothesized that metabolic perturbation may substantially influence cell response to therapies targeting major oncogenes which are involved in active hijacking of neoplastic cell metabolism. In that regard, MYC represents a paradigmatic oncogene as this transcription factor is deregulated in more than 50% of human cancers and reprograms many aspect of cell metabolism. MYC expression is controlled by clusters of super-enhancer genomic regions densely occupied by transcription factors and chromatin regulators ― including BET bromodomain proteins, and CDK7 and CDK9 kinases. Two cohorts of patients with Acute Myeloid Leukemia, AML (TCGA-LAML, n=198 and GSE14468, n=526) were queried with multiple gene sets in order to reveal a core of metabolic gene signatures, which are connected to the folate cycle, and whose activation was poorly correlated with an active MYC transcriptional program in AML. According to these data, we established that folate cycle disruption upon folic acid starvation consistently enhanced resistance to MYC targeting by BET or CDK7 inhibitors (JQ1, OTX015, THZ1) as well as BRD4-directed shRNAs in a large panel of human AML cell lines harboring a wide variety of genetic alterations (n=7), in MLL-translocated primary patient samples with AML (n=4), and in animals injected with MLL-AF9-positive leukemic cells. Using an shRNA-based screening approach against enzymes from the folate cycle, we revealed that the knockdown of the rate-limiting enzyme in the folate cycle, 5,10-methylenetetrahydroflate reductase (MTHFR), significantly increased resistance to OTX015 in AML cell lines (n=4) and in animals transplanted with Mthfr-depleted blasts. Previous reports have identified and extensively studied two common genetic variants in the MTHFR gene, C677T and A1298C, encoding two MTHFR enzyme variants with reduced activity in about 10% of Caucasians. We introduced in KG1a cells these two non-synonymous single nucleotide polymorphisms in MTHFR using CRISPR-Cas9, thereby generating isogenic cell lines exhibiting all combinations of variants. Although the clones which are heterozygous for any of the two variants had similar sensitivity to OTX015 as wild-type clones, 677 TT and 1298 CC homozygous KG1a clones were significantly more resistant to OTX015 than their wild-type counterpart, an effect that was alleviated by exogenous overexpression of wild-type MTHFR or supplementation of cells with the end-product metabolite synthesized by MTHFR, 5-CH3 THF. Consistent with these data, MLL-translocated patients displaying a homozygous and compound heterozygous MTHFR genotype for any of the two variants (n=8) responded significantly less to OTX015 than those with wild-type homozygous and heterozygous MTHFR genotypes (n=8). Finally, we established that the loss of a single copy of Mthfr which phenocopies in mice a partial impairment in MTHFR activity caused by non-synonymous single nucleotide polymorphisms on MTHFR, was sufficient to attenuate sensitivity to JQ1 of MLL-AF9-driven leukemias. Using metabolomics profiling, we pointed out that a major effect of folate cycle disturbance in AML cells is the intracellular accumulation of S-adenosyl-homocysteine, SAH, which is the downstream effector of MTHFR knockdown triggering BET inhibitor resistance. Given that SAH is a potent inhibitor of SAM-dependent methylation reactions, we determined that folate cycle impairment decreases H3K27 and H3K9 methyltransferase activities and subsequent methylation of H3K27 and H3K9 histone marks across the whole genome of AML cells. By combining ChIP- and RNA-sequencing approaches, we demonstrated that decreased methylation levels of H3K27 and H3K9 histone marks upon folate cycle alteration combined with BET inhibition activates SPI1 and IRF / Interferon signaling transcriptional programs. SPI1 knockdown significantly reduced the resistance to OTX015 of AML cells whose MTHFR expression was suppressed or MLL-AF9-transformed Mthfr knockout primary murine cells. Our data provide a rationale for screening MTHFR polymorphisms and the folate cycle status to exclude patients least likely and nominate those most likely to benefit from MYC-targeting therapies. Disclosures Dombret: CELGENE: Consultancy, Honoraria; AGIOS: Honoraria; Institut de Recherches Internationales Servier (IRIS): Research Funding. Stegmaier:Rigel Pharmaceuticals: Consultancy; Novartis: Research Funding.

6 April 2026
Verified
Thesis
Closed access
CVCamille Vaganay
Camille Vaganay
Les Leucémies Aiguës Myéloïdes (LAM) sont un groupe d'hémopathies malignes hétérogènes dont le pronostic demeure défavorable. Son traitement standard repose sur l'utilisation d'une combinaison d'agents chimiothérapeutiques qui permettent une rémission complète chez la majorité de patients mais plus de 50% d'entre-eux rechutent avec une maladie résistante à de nouvelles tentatives de traitement. Un premier axe d'étude s'est intéressé aux mécanismes moléculaires qui sous-tendent la chimiorésistance afin de déterminer de nouvelles stratégies thérapeutiques, adjuvantes à la chimiothérapie et améliorer la survie des patients. Nous avons développé un modèle isogénique de chimiorésistance en utilisant un modèle murin syngénique traité par plusieurs cycles consécutifs de chimiothérapie (5 + 3 de cytarabine et doxorubicine) à une dose maximalement tolérée ayant permis de faire émerger une population de cellules leucémiques chimiorésistantes. Des analyses de transcriptomique ont validé la pertinence de notre modèle et ont mis en évidence des perturbations post-transcriptionnelles majeures affectant l'épissage alternatif. Afin d'identifier les médiateurs fonctionnels de cette chimiorésistance nous avons réalisé un criblage in vivo perte de fonction à l'aide d'une banque de shRNAs dirigés contre les gènes surexprimés de notre signature de chimiorésistance. L'analyse intégrée de nos résultats de criblage et des profils d'épissage ont permis de nominer SRRM1 en tant qu'acteur central de cette chimiorésistance. En déployant une approche orthogonale de phospho-protéomique, nous avons identifié deux protéines à activité sérine/thréonine kinase, PAK1 et les kinases CLK, dont SRRM1 est le substrat. L'inhibition pharmacologique combinée des kinases CLK et de PAK1 in vivo phénocopie la suppression de SRRM1 sur l'altération de l'épissage et affecte majoritairement la viabilité des cellules de LAM chimiorésistantes en restituant notamment leur sensibilité à la chimiothérapie. La pertinence de notre stratégie de ciblage du réseau SRRM1/CLK/PAK1 a été validée in vivo dans des modèles murins de transplantation de cellules murines et humaines chimiorésistantes. Nous avons finalement montré ex vivo que les échantillons de patients atteints de LAM en échec thérapeutique présentent une sensibilité accrue à la combinaison d'inhibiteurs de CLK et PAK1. Cette dernière observation montre que le réseau moléculaire SRRM1/CLK/PAK1 constitue une vulnérabilité thérapeutique de choix afin de circonvenir la résistance aux chimiothérapies dans les LAMs. Un second axe d'étude s'est intéressé à identifier de nouvelles dépendances oncogéniques qui pourraient servir de leviers thérapeutiques prometteurs dans les LAMs. Nous avons réalisé un criblage fonctionnel perte de fonction à large échelle in vivo en ciblant, à l'aide d'une banque de shRNAs, des gènes de réponse au stress cellulaire et mis en évidence VCP, une AAA-ATPase impliquée dans divers mécanismes protéostatiques et dans la réparation des dommages à l'ADN, en tant que vulnérabilité majeure dans les LAMs. Nous avons validé in vitro et in vivo le rôle de VCP dans la détection des dommages à l'ADN et leur réparation et dans la survie et la prolifération leucémique. VCP bénéficie déjà d'inhibiteurs spécifiques mais leur développement clinique n'a pas pu aboutir pour raison de toxicité aggravée chez les sujets traités. Nous avons alors mis au point un nouvel inhibiteur appelé CB-5339 et validé son efficacité anti-leucémique à l'aide de différents modèles. Afin d'anticiper des résistances éventuelles à l'utilisation de cette molécule, nous avons corrélé la cooccurrence de mutations RAS et TP53 à une baisse de sensibilité au CB-5339, suggérant que la sélection de clones co-mutés représente une menace à l'efficacité thérapeutique du CB-5339. Ce dernier fait l'objet d'un essai clinique multicentrique de phase I pour le traitement de LAM en rechute ou réfractaires (NCT04402541).

8 September 2026 in Cell Reports
Verified
Journal Article
Open access
CDChristopher D. Delaney
Christopher D. Delaney
MLMin Lu
Min Lu
SZSeth P. Zimmerman
Seth P. Zimmerman
YMYingying Meng
Yingying Meng
CVCamille Vaganay
Camille Vaganay
KWKris C. Wood
Kris C. Wood
Many cancers are driven by mutationally altered transcription factors (TFs) that rewire cells to an oncogenic state. Cells must activate specific mechanisms to tolerate the burden of oncogenic TF activity. To define such mechanisms, we focused on a canonical oncogenic fusion protein-driven cancer, alveolar rhabdomyosarcoma (ARMS), where the PAX3::FOXO1 fusion protein hyperactivates and mislocalizes PAX3 and FOXO1 TF functions. Employing sequential functional genomic CRISPR-Cas9 screens, we identified FANCM, a DNA translocase in the Fanconi anemia pathway, as a selective dependency in PAX3::FOXO1+ ARMS. FANCM loss reduces fusion protein levels, induces myogenic differentiation, and disrupts the PAX3::FOXO1 transcriptional program, thereby halting oncogenic proliferation. Mechanistically, FANCM depletion exacerbates replication stress (RS) and DNA damage signaling, with chromatin-associated RS enriched at PAX3::FOXO1 target gene loci, resulting in selective downregulation of the oncogenic program. CRISPR exon-tiling screens prioritized FANCM's helicase and DNA-binding domains as essential for this dependency, linking FANCM-mediated replication fork binding to sustained oncogenesis.

8 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
CVCamille Vaganay
Camille Vaganay
FLFrank Ling
Frank Ling
LKLois M. Kelly
Lois M. Kelly
JCJuliette Charles
Juliette Charles
PMPaul-Arthur Meslin
Paul-Arthur Meslin
APAlexandre Puissant
Alexandre Puissant
Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.